India's drug regulators face challenge ensuring safety of numerous cough syrup brands.
India's drug regulators face a significant challenge in ensuring the safety and quality of over 2,000 cough syrup brands, especially after recent incidents of contaminated syrups causing deaths abroad. The article highlights the fragmented regulatory landscape, with both central and state bodies responsible for oversight, leading to inconsistencies and loopholes. Concerns are raised about the lack of robust testing, inadequate inspections, and the proliferation of unapproved formulations. The author calls for a unified, stringent regulatory framework, increased transparency, and enhanced testing capabilities to protect public health and restore confidence in India's pharmaceutical industry.
Key Points
- India's drug regulators struggle to ensure the safety of over 2,000 cough syrup brands, particularly after contamination incidents.
- The fragmented regulatory system, involving both central and state bodies, leads to inconsistencies and oversight gaps.
- Concerns include inadequate testing, insufficient inspections, and the proliferation of unapproved or substandard formulations.
- A unified, stringent regulatory framework, increased transparency, and enhanced testing capabilities are urgently needed.
- Strengthening drug regulation is crucial to protect public health and restore confidence in India's pharmaceutical industry.
Exam Facts
- India has over 2,000 cough syrup brands.
- The Drugs and Cosmetics Act, 1940, governs drug regulation in India.
- The Central Drugs Standard Control Organisation (CDSCO) is the central regulator.
- The article mentions "diethylene glycol" and "ethylene glycol" as contaminants.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.